Rinvoq-话题@MedSci

#Rinvoq#

9篇内容 | 1172人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1675192, encodeId=b92016e519274, content=<a href='/topic/show?id=dcf4154883a' target=_blank style='color:#2F92EE;'>#Rinvoq#</a>, objectTitle=英国NICE推荐Rinvoq用于银屑病关节炎患者, objectType=article, longId=294120, objectId=a9742941208a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a9742941208a, replyNumber=0, likeNumber=112, createdTime=2022-03-17, rootId=0, userName=fanweitanzhen, userId=ae2827174135, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a9742941208a, moduleTitle=英国NICE推荐Rinvoq用于银屑病关节炎患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a9742941208a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1675191, encodeId=600516e51911f, content=<a href='/topic/show?id=dcf4154883a' target=_blank style='color:#2F92EE;'>#Rinvoq#</a>, objectTitle=NICE支持Rinvoq治疗严重的活动性类风湿关节炎, objectType=article, longId=203140, objectId=2361203140f1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2361203140f1, replyNumber=0, likeNumber=117, createdTime=2020-11-17, rootId=0, userName=fanweitanzhen, userId=ae2827174135, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2361203140f1, moduleTitle=NICE支持Rinvoq治疗严重的活动性类风湿关节炎, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2361203140f1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1675188, encodeId=2cca16e5188ca, content=<a href='/topic/show?id=dcf4154883a' target=_blank style='color:#2F92EE;'>#Rinvoq#</a>, objectTitle=AbbVie向美国和欧洲药品管理局提交营销申请，将JAK抑制剂Rinvoq用于治疗银屑病关节炎, objectType=article, longId=195324, objectId=869819532415, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=869819532415, replyNumber=0, likeNumber=66, createdTime=2020-09-27, rootId=0, userName=fanweitanzhen, userId=ae2827174135, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=869819532415, moduleTitle=AbbVie向美国和欧洲药品管理局提交营销申请，将JAK抑制剂Rinvoq用于治疗银屑病关节炎, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=869819532415)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1675189, encodeId=21a816e518905, content=<a href='/topic/show?id=dcf4154883a' target=_blank style='color:#2F92EE;'>#Rinvoq#</a>, objectTitle=艾伯维的JAK抑制剂Rinvoq，III期临床显示出治疗特应性皮炎的潜力, objectType=article, longId=196190, objectId=6f67196190f1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6f67196190f1, replyNumber=0, likeNumber=76, createdTime=2021-05-12, rootId=0, userName=fanweitanzhen, userId=ae2827174135, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6f67196190f1, moduleTitle=艾伯维的JAK抑制剂Rinvoq，III期临床显示出治疗特应性皮炎的潜力, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6f67196190f1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1675190, encodeId=d17116e51900e, content=<a href='/topic/show?id=dcf4154883a' target=_blank style='color:#2F92EE;'>#Rinvoq#</a>, objectTitle=JAK抑制剂Rinvoq治疗特应性皮炎：III期临床疗效显著, objectType=article, longId=197968, objectId=d9bf19e9686d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d9bf19e9686d, replyNumber=0, likeNumber=76, createdTime=2021-03-28, rootId=0, userName=fanweitanzhen, userId=ae2827174135, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d9bf19e9686d, moduleTitle=JAK抑制剂Rinvoq治疗特应性皮炎：III期临床疗效显著, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d9bf19e9686d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1675187, encodeId=d82e16e518773, content=<a href='/topic/show?id=dcf4154883a' target=_blank style='color:#2F92EE;'>#Rinvoq#</a>, objectTitle=艾伯维的口服JAK抑制剂RINVOQ获得加拿大批准，用于治疗中度至重度活动性类风湿性关节炎, objectType=article, longId=185935, objectId=6a1818593535, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6a1818593535, replyNumber=0, likeNumber=94, createdTime=2020-09-10, rootId=0, userName=fanweitanzhen, userId=ae2827174135, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6a1818593535, moduleTitle=艾伯维的口服JAK抑制剂RINVOQ获得加拿大批准，用于治疗中度至重度活动性类风湿性关节炎, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6a1818593535)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1675185, encodeId=727416e51858f, content=<a href='/topic/show?id=dcf4154883a' target=_blank style='color:#2F92EE;'>#Rinvoq#</a>, objectTitle=5.9万美元/年！艾伯维官宣JAK抑制剂Rinvoq定价，8月底登陆美国！, objectType=article, longId=178087, objectId=e5861e8087e1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e5861e8087e1, replyNumber=0, likeNumber=80, createdTime=2020-03-30, rootId=0, userName=fanweitanzhen, userId=ae2827174135, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e5861e8087e1, moduleTitle=5.9万美元/年！艾伯维官宣JAK抑制剂Rinvoq定价，8月底登陆美国！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e5861e8087e1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1675186, encodeId=aace16e5186a6, content=<a href='/topic/show?id=dcf4154883a' target=_blank style='color:#2F92EE;'>#Rinvoq#</a>, objectTitle=艾伯维的JAK抑制剂Rinvoq，获得欧盟批准治疗类风湿性关节炎, objectType=article, longId=185034, objectId=d32d1850343b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d32d1850343b, replyNumber=0, likeNumber=65, createdTime=2020-05-24, rootId=0, userName=fanweitanzhen, userId=ae2827174135, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d32d1850343b, moduleTitle=艾伯维的JAK抑制剂Rinvoq，获得欧盟批准治疗类风湿性关节炎, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d32d1850343b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1675184, encodeId=7d1c16e518407, content=<a href='/topic/show?id=dcf4154883a' target=_blank style='color:#2F92EE;'>#Rinvoq#</a>, objectTitle=FDA批准JAK抑制剂Rinvoq用于中度至重度类风湿性关节炎, objectType=article, longId=177845, objectId=6bec1e7845da, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6bec1e7845da, replyNumber=0, likeNumber=77, createdTime=2020-03-21, rootId=0, userName=fanweitanzhen, userId=ae2827174135, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6bec1e7845da, moduleTitle=FDA批准JAK抑制剂Rinvoq用于中度至重度类风湿性关节炎, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6bec1e7845da)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

Rinvoq

2020-05-29

fanweitanzhen (审核中...)

前往app查看评论内容

#Rinvoq#

英国NICE推荐Rinvoq用于银屑病关节炎患者

2022-03-17

fanweitanzhen (审核中...)

前往app查看评论内容

#Rinvoq#

NICE支持Rinvoq治疗严重的活动性类风湿关节炎

2020-11-17

fanweitanzhen (审核中...)

前往app查看评论内容

#Rinvoq#

AbbVie向美国和欧洲药品管理局提交营销申请，将JAK抑制剂Rinvoq用于治疗银屑病关节炎

2020-09-27

fanweitanzhen (审核中...)

前往app查看评论内容

#Rinvoq#

艾伯维的JAK抑制剂Rinvoq，III期临床显示出治疗特应性皮炎的潜力

2021-05-12

fanweitanzhen (审核中...)

前往app查看评论内容

#Rinvoq#

JAK抑制剂Rinvoq治疗特应性皮炎：III期临床疗效显著

2021-03-28

fanweitanzhen (审核中...)

前往app查看评论内容

#Rinvoq#

艾伯维的口服JAK抑制剂RINVOQ获得加拿大批准，用于治疗中度至重度活动性类风湿性关节炎

2020-09-10

fanweitanzhen (审核中...)

前往app查看评论内容

#Rinvoq#

5.9万美元/年！艾伯维官宣JAK抑制剂Rinvoq定价，8月底登陆美国！

2020-03-30

fanweitanzhen (审核中...)

前往app查看评论内容

#Rinvoq#

艾伯维的JAK抑制剂Rinvoq，获得欧盟批准治疗类风湿性关节炎

2020-05-24

fanweitanzhen (审核中...)

前往app查看评论内容

#Rinvoq#

FDA批准JAK抑制剂Rinvoq用于中度至重度类风湿性关节炎

2020-03-21

科室
- - 订阅+
  - 更多科室
工具
服务